Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
(Posted: 03/20/2013) - Taking adjuvant tamoxifen for 10 years after primary treatment leads to a greater reduction in breast cancer recurrences and deaths than taking the drug for only 5 years, according to the results of a large international clinical trial.
Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancer
(Posted: 02/07/2013) - Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an interim analysis of a large, randomized clinical trial.
Video Eases End-of-Life Care Discussions
(Posted: 01/12/2010, Updated: 01/03/2013) - Patients with advanced cancer who watched a video that depicts options for end-of-life care were more certain of their end-of-life decision making than patients who only listened to a verbal narrative and were likely to choose comfort care over aggressive medical care for their end-of-life care preferences, according to an article published online November 30, 2009, in the Journal of Clinical Oncology.
Abiraterone Improves Survival in Metastatic Prostate Cancer
(Posted: 07/27/2011, Updated: 12/31/2012) - A multinational phase III trial found that the drug abiraterone acetate prolonged the median survival of patients with metastatic castration-resistant prostate cancer by 4 months compared with patients who received a placebo.
New Drug Shows Promise against Drug-Resistant Leukemias
(Posted: 12/17/2012) - A new drug called ponatinib may be a new treatment option for patients with chronic myeloid leukemia (CML) that is resistant to other therapies, according to results of two early clinical trials.